ZA202004827B - Anti-cd73 antibodies and uses thereof - Google Patents
Anti-cd73 antibodies and uses thereofInfo
- Publication number
- ZA202004827B ZA202004827B ZA2020/04827A ZA202004827A ZA202004827B ZA 202004827 B ZA202004827 B ZA 202004827B ZA 2020/04827 A ZA2020/04827 A ZA 2020/04827A ZA 202004827 A ZA202004827 A ZA 202004827A ZA 202004827 B ZA202004827 B ZA 202004827B
- Authority
- ZA
- South Africa
- Prior art keywords
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862640955P | 2018-03-09 | 2018-03-09 | |
| US201862721044P | 2018-08-22 | 2018-08-22 | |
| US201862786598P | 2018-12-31 | 2018-12-31 | |
| PCT/US2019/020688 WO2019173291A1 (en) | 2018-03-09 | 2019-03-05 | Anti-cd73 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202004827B true ZA202004827B (en) | 2023-06-28 |
Family
ID=67846304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/04827A ZA202004827B (en) | 2018-03-09 | 2020-08-04 | Anti-cd73 antibodies and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11299550B2 (OSRAM) |
| EP (1) | EP3762030A4 (OSRAM) |
| JP (2) | JP7334177B2 (OSRAM) |
| KR (2) | KR102804816B1 (OSRAM) |
| CN (2) | CN118955714A (OSRAM) |
| AU (1) | AU2019231172B2 (OSRAM) |
| BR (1) | BR112020016049A2 (OSRAM) |
| CA (1) | CA3090008A1 (OSRAM) |
| IL (1) | IL276950B1 (OSRAM) |
| MX (1) | MX2020009366A (OSRAM) |
| SG (1) | SG11202007199XA (OSRAM) |
| WO (1) | WO2019173291A1 (OSRAM) |
| ZA (1) | ZA202004827B (OSRAM) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019067425A1 (en) | 2017-09-26 | 2019-04-04 | The Trustees Of The University Of Pennsylvania | COMPOSITIONS AND METHODS FOR TREATING CARDIAC DISEASE BY REDIRECTED T-CELL IMMUNOTHERAPIES |
| JP7474709B2 (ja) | 2018-02-27 | 2024-04-25 | インサイト・コーポレイション | Ａ２ａ／ａ２ｂ阻害剤としてのイミダゾピリミジン及びトリアゾロピリミジン |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| AU2019297361B2 (en) | 2018-07-05 | 2024-06-27 | Incyte Corporation | Fused pyrazine derivatives as A2A / A2B inhibitors |
| WO2020072996A1 (en) | 2018-10-05 | 2020-04-09 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Newborn screening for primary immunodeficiencies, cystinosis, and wilson disease |
| CN111434688A (zh) * | 2019-01-11 | 2020-07-21 | 上海开拓者生物医药有限公司 | Cd73抗体及其制备方法和应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN114761036B (zh) * | 2019-09-23 | 2025-09-30 | 宾夕法尼亚大学董事会 | 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体 |
| AU2020353000A1 (en) | 2019-09-23 | 2022-04-07 | The Trustees Of The University Of Pennsylvania | Disrupting tumor tissues by targeting fibroblast activation protein (FAP) |
| PH12022551150A1 (en) * | 2019-11-15 | 2023-10-09 | Genzyme Corp | Biparatopic cd73 antibodies |
| CN114929276A (zh) * | 2019-11-20 | 2022-08-19 | 爱维盛新药股份有限公司 | 靶向人类cd47蛋白的单克隆抗体 |
| JP2023511652A (ja) * | 2019-12-17 | 2023-03-22 | フェインズ セラピューティクス，インコーポレーテッド | 鎖間システインが選択的にマッチングされた二重特異性抗体及びその使用 |
| KR20220137013A (ko) | 2020-01-03 | 2022-10-11 | 인사이트 코포레이션 | Cd73 억제제 및 a2a/a2b 아데노신 수용체 억제제 병용 요법 |
| EP4084825A1 (en) * | 2020-01-03 | 2022-11-09 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| WO2021202807A1 (en) * | 2020-03-31 | 2021-10-07 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Proteomic screening for lysosomal storage diseases |
| CA3176321A1 (en) * | 2020-04-22 | 2021-10-28 | Peng Zhang | Anti-cd73-anti-pd-1 bispecific antibody and use thereof |
| CN113527489B (zh) * | 2020-04-22 | 2024-04-26 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| BR112022021992A2 (pt) * | 2020-04-30 | 2023-01-03 | Arch Oncology Inc | Método de tratamento de câncer em um sujeito em necessidade do mesmo |
| WO2022037531A1 (zh) * | 2020-08-17 | 2022-02-24 | 中山康方生物医药有限公司 | 抗cd73的抗体及其用途 |
| CA3196299A1 (en) * | 2020-10-23 | 2022-04-28 | Baiyong Li | Anti-cd73 antibody and use thereof |
| CN114456268B (zh) * | 2020-11-09 | 2023-08-18 | 江苏中新医药有限公司 | 抗胞外-5’-核苷酸酶的抗体序列 |
| US20240026024A1 (en) * | 2020-12-11 | 2024-01-25 | Shanghai Huaota Biopharmaceutical Co., Ltd. | Cd73 antigen-binding protein and application thereof |
| TW202241441A (zh) | 2020-12-29 | 2022-11-01 | 美商英塞特公司 | 包含ａ２ａ／ａ２ｂ抑制劑、ｐｄ－１／ｐｄ－ｌ１抑制劑及抗ｃｄ７３抗體之組合療法 |
| CN113061177B (zh) * | 2020-12-31 | 2022-07-01 | 浙江大学 | 一种cd73酶活性相关的抗原表位及针对该表位的特异性抗体的制备方法 |
| WO2022179039A1 (zh) * | 2021-02-24 | 2022-09-01 | 苏州近岸蛋白质科技股份有限公司 | 抗人cd73抗体及其应用 |
| GB202105110D0 (en) * | 2021-04-09 | 2021-05-26 | Cancer Research Tech Ltd | Anti-CD73 antibodies |
| IL310866A (en) * | 2021-08-19 | 2024-04-01 | Adicet Therapeutics Inc | Methods for detection of membrane bound glypican-3 |
| CN116265486A (zh) * | 2021-12-17 | 2023-06-20 | 三生国健药业（上海）股份有限公司 | 结合人cd73的抗体、其制备方法和用途 |
| US12187806B2 (en) * | 2022-03-04 | 2025-01-07 | Development Center For Biotechnology | Anti-CD73 antibodies and use thereof |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN116063467B (zh) * | 2022-08-24 | 2025-10-14 | 浙江大学医学院附属第一医院 | 抗h10亚型禽流感病毒血凝素蛋白单克隆抗体1f3及其在检测中的应用 |
| WO2024243189A2 (en) * | 2023-05-22 | 2024-11-28 | Board Of Regents, The University Of Texas System | Antigen binding proteins targeting pd-1 |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| CN117567632B (zh) * | 2023-11-27 | 2025-10-24 | 福州迈新生物技术开发有限公司 | 抗cd73蛋白单克隆抗体及其制备方法和应用 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| FR3011240A1 (fr) | 2013-10-01 | 2015-04-03 | Centre Nat Rech Scient | Inhibiteurs de 5'-nucleotidases et leurs utilisations therapeutiques |
| WO2015164573A1 (en) | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| US10766966B2 (en) | 2014-10-10 | 2020-09-08 | Innate Pharma | CD73 blockade |
| CN112778418B (zh) * | 2014-11-10 | 2025-04-22 | 免疫医疗有限公司 | 对cd73具有特异性的结合分子及其用途 |
| HK1246304A1 (zh) | 2014-11-11 | 2018-09-07 | Medimmune Limited | 包含抗cd73抗体和a2a受体抑制剂的治疗组合及其用途 |
| HRP20201756T8 (hr) | 2014-11-21 | 2021-08-20 | Bristol-Myers Squibb Company | Antitijela koja sadrže modificirane regije teškog lanca |
| TWI711630B (zh) | 2014-11-21 | 2020-12-01 | 美商必治妥美雅史谷比公司 | 抗ｃｄ７３抗體及其用途 |
| EP3259288A1 (en) | 2015-02-20 | 2017-12-27 | Innate Pharma | Cd73 blockade |
| WO2017064043A1 (en) | 2015-10-12 | 2017-04-20 | Innate Pharma | Cd73 blocking agents |
| WO2017100670A1 (en) * | 2015-12-09 | 2017-06-15 | Corvus Pharmaceuticals, Inc. | Humanized anti-cd73 antibodies |
| WO2017118613A1 (en) | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| CA3016187A1 (en) * | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| US10793636B2 (en) | 2016-07-11 | 2020-10-06 | Corvus Pharmaceuticals, Inc. | Anti-CD73 antibodies |
-
2019
- 2019-03-05 EP EP19764477.6A patent/EP3762030A4/en active Pending
- 2019-03-05 JP JP2020546997A patent/JP7334177B2/ja active Active
- 2019-03-05 BR BR112020016049-0A patent/BR112020016049A2/pt unknown
- 2019-03-05 SG SG11202007199XA patent/SG11202007199XA/en unknown
- 2019-03-05 MX MX2020009366A patent/MX2020009366A/es unknown
- 2019-03-05 WO PCT/US2019/020688 patent/WO2019173291A1/en not_active Ceased
- 2019-03-05 KR KR1020207027633A patent/KR102804816B1/ko active Active
- 2019-03-05 CN CN202411072731.7A patent/CN118955714A/zh active Pending
- 2019-03-05 CA CA3090008A patent/CA3090008A1/en active Pending
- 2019-03-05 CN CN201980018305.6A patent/CN111867628B/zh active Active
- 2019-03-05 KR KR1020257013451A patent/KR20250065424A/ko active Pending
- 2019-03-05 US US15/733,540 patent/US11299550B2/en active Active
- 2019-03-05 AU AU2019231172A patent/AU2019231172B2/en active Active
-
2020
- 2020-08-04 ZA ZA2020/04827A patent/ZA202004827B/en unknown
- 2020-08-26 IL IL276950A patent/IL276950B1/en unknown
-
2023
- 2023-08-14 JP JP2023132024A patent/JP7636483B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| IL276950A (en) | 2020-10-29 |
| JP7636483B2 (ja) | 2025-02-26 |
| AU2019231172A1 (en) | 2020-09-03 |
| CN118955714A (zh) | 2024-11-15 |
| WO2019173291A1 (en) | 2019-09-12 |
| JP2021516057A (ja) | 2021-07-01 |
| KR102804816B1 (ko) | 2025-05-09 |
| NZ766968A (en) | 2024-12-20 |
| AU2019231172B2 (en) | 2023-08-24 |
| BR112020016049A2 (pt) | 2020-12-08 |
| CN111867628B (zh) | 2024-08-23 |
| EP3762030A1 (en) | 2021-01-13 |
| CA3090008A1 (en) | 2019-09-12 |
| US11299550B2 (en) | 2022-04-12 |
| JP7334177B2 (ja) | 2023-08-28 |
| CN111867628A (zh) | 2020-10-30 |
| MX2020009366A (es) | 2020-10-14 |
| US20200399389A1 (en) | 2020-12-24 |
| EP3762030A4 (en) | 2022-01-05 |
| JP2023162257A (ja) | 2023-11-08 |
| KR20250065424A (ko) | 2025-05-12 |
| IL276950B1 (en) | 2025-12-01 |
| SG11202007199XA (en) | 2020-09-29 |
| KR20200128542A (ko) | 2020-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276950A (en) | Anti-CD73 antibodies and uses thereof | |
| IL282968A (en) | Anti-NKG2A antibodies and their use | |
| SG11202105885WA (en) | Anti-claudin antibodies and uses thereof | |
| IL274152B (en) | Anti-galectin-9 antibodies and their uses | |
| IL267942B (en) | Anti-cd73 antibodies and uses thereof | |
| IL268734A (en) | Anti-LAG-3 antibodies and uses thereof | |
| IL275826A (en) | Anti-mct1 antibodies and their uses | |
| IL268700A (en) | Anti-PHF-tau antibodies and uses thereof | |
| ZA202006066B (en) | Anti-hla-g antibodies and use thereof | |
| IL269134A (en) | Antibodies against PAR2 and their use | |
| IL289585A (en) | DLL3-targeted antibodies and uses thereof | |
| IL273157A (en) | Antibodies specific to AXL and their uses | |
| SG11202009772PA (en) | Anti-dll3 antibodies and uses thereof | |
| IL281202A (en) | Anti-TNFRSF9 antibodies and uses thereof | |
| ZA202100714B (en) | Anti-npr1 antibodies and uses thereof | |
| IL280321A (en) | Antibodies against CXCR2 and their uses | |
| IL291027A (en) | Anti-steap1 antibodies and uses thereof | |
| IL277075A (en) | Anti-PHF-tau antibodies and uses thereof | |
| SG11202009625WA (en) | Anti-trem-1 antibodies and uses thereof | |
| IL272476A (en) | Anti-Apelin antibodies and their uses | |
| SG11202112112UA (en) | Anti-galectin-9 antibodies and uses thereof | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| IL277330A (en) | Anti-IL-27 antibodies and uses thereof | |
| SG11202012680TA (en) | Anti-l1cam antibodies and uses thereof | |
| IL276548A (en) | Binding antibodies - BCMA and their uses |